A brief history of DMT
DMT, short for N, N-Dimethyltryptamine, is a naturally-occurring, fast-acting psychoactive molecule. Also described as the…
5 Most Important Psychedelic Clinical Trials in 2022
James Halifax, Psychedelic Spotlight writer and their resident psychedelic investor, recently covered his 5 most…
DMT-Assisted Therapy May Address Root Cause of Major Depression
Gail Dutton of BioSpace.com, a leading online biotechnology source for breaking industry news and expert analysis,…
Small Pharma CEO Peter Rand & CMSO Dr Carol Routledge at the 34th Annual Roth Conference
View Small Pharma’s Fireside Chat Webcast from the 34th Annual Roth Conference Monday, March 14 at 3:30…
Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical…
World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic…
The Latest in DMT Research: Leading Companies and Key Studies
Truffle Report put together this roundup of the top corporate and scientific developments involving the…
What is DMT therapy?
By Dr Carol Routledge, Chief Medical & Scientific Officer, as originally featured in Drug Science DMT-assisted…
DMT-assisted therapy: changing the way we think about depressive disorders
Our CMSO Carol Routledge spoke to Bioscience Today about the world-leading psychedelic therapy research happening…
The Psychedelic Investor asks: Can DMT Treat Depression?
Can DMT treat depression? James Hallifax, of the Psychedelic Spotlight podcast, sits down to interview…